Literature DB >> 30201396

CpAMs induce assembly of HBV capsids with altered electrophoresis mobility: Implications for mechanism of inhibiting pgRNA packaging.

Shuo Wu1, Yue Luo2, Usha Viswanathan3, John Kulp3, Junjun Cheng3, Zhanying Hu3, Qifang Xu4, Yan Zhou4, Guo-Zhong Gong5, Jinhong Chang3, Yuhuan Li6, Ju-Tao Guo7.   

Abstract

Native agarose gel electrophoresis-based particle gel assay has been commonly used for examination of hepatitis B virus (HBV) capsid assembly and pregenomic RNA encapsidation in HBV replicating cells. Interestingly, treatment of cells with several chemotypes of HBV core protein allosteric modulators (CpAMs) induced the assembly of both empty and DNA-containing capsids with faster electrophoresis mobility. In an effort to determine the physical basis of CpAM-induced capsid mobility shift, we found that the surface charge, but not the size, of capsids is the primary determinant of electrophoresis mobility. Specifically, through alanine scanning mutagenesis analysis of twenty-seven charged amino acids in core protein assembly domain and hinge region, we showed that except for K7 and E8, substitution of glutamine acid (E) or aspartic acid (D) on the surface of capsids reduced their mobility, but substitution of lysine (K) or arginine (R) on the surface of capsids increased their mobility in variable degrees. However, alanine substitution of the charged amino acids that are not exposed on the surface of capsid did not apparently alter capsid mobility. Hence, CpAM-induced electrophoresis mobility shift of capsids may reflect the global alteration of capsid structure that changes the exposure and/or ionization of charged amino acid side chains of core protein. Our findings imply that CpAM inhibition of pgRNA encapsidation is possibly due to the assembly of structurally altered nucleocapsids. Practically, capsid electrophoresis mobility shift is a diagnostic marker of compounds that target core protein assembly and predicts sensitivity of HBV strains to specific CpAMs.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30201396      PMCID: PMC8034245          DOI: 10.1016/j.antiviral.2018.09.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  44 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

2.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity.

Authors:  J J Ott; G A Stevens; J Groeger; S T Wiersma
Journal:  Vaccine       Date:  2012-01-24       Impact factor: 3.641

Review 3.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

4.  The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription.

Authors:  Zhenning Tan; Karolyn Pionek; Nuruddin Unchwaniwala; Megan L Maguire; Daniel D Loeb; Adam Zlotnick
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

Review 5.  Capsid proteins of enveloped viruses as antiviral drug targets.

Authors:  Klaus Klumpp; Thibaut Crépin
Journal:  Curr Opin Virol       Date:  2014-03-05       Impact factor: 7.090

6.  Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus.

Authors:  Chunxiao Xu; Haitao Guo; Xiao-Ben Pan; Richeng Mao; Wenquan Yu; Xiaodong Xu; Lai Wei; Jinhong Chang; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators.

Authors:  Sarah P Katen; Srinivas Reddy Chirapu; M G Finn; Adam Zlotnick
Journal:  ACS Chem Biol       Date:  2010-10-04       Impact factor: 5.100

8.  Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure.

Authors:  Sarah P Katen; Zhenning Tan; Srinivas Reddy Chirapu; M G Finn; Adam Zlotnick
Journal:  Structure       Date:  2013-07-18       Impact factor: 5.006

9.  A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation.

Authors:  Ya-Juan Wang; Dong Lu; Yi-Bin Xu; Wei-Qiang Xing; Xian-Kun Tong; Gui-Feng Wang; Chun-Lan Feng; Pei-Lan He; Li Yang; Wei Tang; You-Hong Hu; Jian-Ping Zuo
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

10.  HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways.

Authors:  Fang Guo; Qiong Zhao; Muhammad Sheraz; Junjun Cheng; Yonghe Qi; Qing Su; Andrea Cuconati; Lai Wei; Yanming Du; Wenhui Li; Jinhong Chang; Ju-Tao Guo
Journal:  PLoS Pathog       Date:  2017-09-25       Impact factor: 6.823

View more
  8 in total

1.  Discovery of Novel Hepatitis B Virus Nucleocapsid Assembly Inhibitors.

Authors:  Xuexiang Zhang; Junjun Cheng; Julia Ma; Zhanying Hu; Shuo Wu; Nicky Hwang; John Kulp; Yanming Du; Ju-Tao Guo; Jinhong Chang
Journal:  ACS Infect Dis       Date:  2018-12-19       Impact factor: 5.084

Review 2.  Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B.

Authors:  Usha Viswanathan; Nagraj Mani; Zhanying Hu; Haiqun Ban; Yanming Du; Jin Hu; Jinhong Chang; Ju-Tao Guo
Journal:  Antiviral Res       Date:  2020-08-17       Impact factor: 5.970

3.  A New Role for Capsid Assembly Modulators To Target Mature Hepatitis B Virus Capsids and Prevent Virus Infection.

Authors:  Chunkyu Ko; Romina Bester; Xue Zhou; Zhiheng Xu; Christoph Blossey; Julia Sacherl; Florian W R Vondran; Lu Gao; Ulrike Protzer
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

4.  Protein phosphatase 1 catalyzes HBV core protein dephosphorylation and is co-packaged with viral pregenomic RNA into nucleocapsids.

Authors:  Zhanying Hu; Haiqun Ban; Haiyan Zheng; Mingliang Liu; Jinhong Chang; Ju-Tao Guo
Journal:  PLoS Pathog       Date:  2020-07-23       Impact factor: 6.823

5.  Synthesis of 4-oxotetrahydropyrimidine-1(2H)-carboxamides derivatives as capsid assembly modulators of hepatitis B virus.

Authors:  Nicky Hwang; Haiqun Ban; Junjun Chen; Julia Ma; Hui Liu; Patrick Lam; John Kulp; Stephan Menne; Jinhong Chang; Ju-Tao Guo; Yanming Du
Journal:  Med Chem Res       Date:  2021-01-11       Impact factor: 1.965

6.  The HBV Core Protein and Core Particle Both Bind to the PPiase Par14 and Par17 to Enhance Their Stabilities and HBV Replication.

Authors:  Umar Saeed; Zahra Zahid Piracha; Hyeonjoong Kwon; Jumi Kim; Fadia Kalsoom; Yong-Joon Chwae; Sun Park; Ho-Joon Shin; Hyun Woong Lee; Jin Hong Lim; Kyongmin Kim
Journal:  Front Microbiol       Date:  2021-12-14       Impact factor: 5.640

7.  Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis.

Authors:  Hui Liu; Junjun Cheng; Usha Viswanathan; Jinhong Chang; Fengmin Lu; Ju-Tao Guo
Journal:  PLoS Pathog       Date:  2021-11-09       Impact factor: 6.823

8.  Design and Synthesis of Hepatitis B Virus (HBV) Capsid Assembly Modulators and Evaluation of Their Activity in Mammalian Cell Model.

Authors:  Karina Spunde; Brigita Vigante; Unda Nelda Dubova; Anda Sipola; Irena Timofejeva; Anna Zajakina; Juris Jansons; Aiva Plotniece; Karlis Pajuste; Arkadij Sobolev; Ruslan Muhamadejev; Kristaps Jaudzems; Gunars Duburs; Tatjana Kozlovska
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.